JPRN-UMIN000030702Completed未知
A study for safety evaluation and immune effect of excess consumption of plant extract for 4 weeks. - A study for safety evaluation and immune effect of excess consumption of plant extract for 4 weeks.
CPCC Company Limited0 sites12 target enrollmentStarted: January 5, 2018Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 12
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 59years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1) Subjects who have treated or taken medicine for perennial allergic rhinitis from 4 weeks short the end of the study. (2) Subjects who planning some treatment during the examination period. (3) Subjects who having Food for Specified Health Uses (FOSHU) and/or health food. (4) Pregnant or expected pregnant, and lactating women. (5) Subjects who have previous and/or current medical history of serious disease in heart, liver, kidney. (6) Subjects who excessive alcohol intake. (7) Subjects who have smoking habit. (8) Subjects who have extremely irregular dining habits, and subjects who have midnight work or irregular shift work. (9) Subjects who have previous medical history of drug and/or food, allergy, especially for Shiso leaf. (10) Subjects who are participating the other clinical tests. Subjects who participated within 4-weeks prior to the current study and/or who plan to participate the other clinical tests. (11) Subjects who donated over 200mL blood and/or blood components within the last one month to the current study. (12) Subjects who donated over 400mL blood and/or blood components within the last three month to the current study. (13) Females who donated over 400mL blood and/or blood components within the last four month to the current study. (14) Males who will be collected over 1200mL blood and/or blood components, when the sampling amounts within the last twelve month are adding to the planned sampling amounts of this study. (15) Females who will be collected over 800mL blood and/or blood components when, the sampling amounts within the last twelve month are adding to the planned sampling amounts of this study. (16) Others who have been determined ineligible by principal investigator or sub-investigator.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Study of increasing doses of genetically modified GD2-specific T cells in patients with metastatic melanoma and refractory solid tumoursMetastatic melanomaRefractory solid tumoursCancer - Malignant melanomaACTRN12613000198729Royal Adelaide Hospital Cancer Centre12
Completed
Phase 3
Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in IndiaCTRI/2010/091/000020Sanofi Pasteur SA100
Completed
Phase 1
Reactogenicity and Immunogenicity of the pentavalent vaccine DPT-HB+Hib. Schedule 2-4-6 months.Prophylaxis against infections diseases: Diphtheria, Tetanus, B. pertussis, H. influenzae type b and hepatitis B.RPCEC00000103Center for Genetic Engineering and Biotechnology (CIGB).624
Not yet recruiting
Phase 1
ABDALA Clinical StudyCOVID-19SARS-CoV2Disease PreventionCoronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusRPCEC00000346Center for Genetic Engineering and Biotechnology (CIGB), in Havana
Not yet recruiting
Phase 1
Safety and immunogenicity of VCN7-T in infants of 2 and 3 months. Phase I/II.Pneumococcal diseaseHealthy VolunteersPneumococcal InfectionsStreptococcal InfectionsGram-Positive Bacterial InfectionsRPCEC00000243Finlay Institute Vaccine880